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The purpose of this study was the evaluation of the
xanthine oxidase (XO) inhibition produced by some
synthetic 2-styrylchromones. Ten polyhydroxylated
derivatives with several substitution patterns were
synthesised, and these and a positive control, allopur-
inol, were tested for their effects on XO activity by
measuring the formation of uric acid from xanthine. The
synthesised 2-styrylchromones inhibited xanthine oxi-
dase in a concentration-dependent and non-competitive
manner. Some IC50 values found were as low as 0.55mM,
which, by comparison with the IC50 found for allopur-
inol (5.43mM), indicates promising new inhibitors.
Those 2-styrylchromones found to be potent XO
inhibitors should be further evaluated as potential
agents for the treatment of pathologies related to the
enzyme’s activity, as is the case of gout, ischaemia/
reperfusion damage, hypertension, hepatitis and cancer.
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INTRODUCTION
2-Styrylchromones are a small group of natural
heterocyclic compounds. Only two natural 2-styr-
ylchromones are known and they were extracted
from the blue-green algae Chrysophaem taylori in the
1980s.1,2 The synthesis of this class of compounds
commenced about six decades prior to the isolation
of the first natural product.3 Natural derivatives
have demonstrated cytotoxic activity against leukae-
mia cells, while those obtained by synthesis have
exhibited anti-allergic, antitumour and anticancer
properties.1,2,4,5
2-Styrylchromones (Figure 1) have a common
structural feature with flavones in containing the
benzopyrone moiety. Taking into account that
flavones are known to be xanthine oxidase (XO)
inhibitors,6 – 9 the evaluation of this activity for 2-
styrylchromones was thought to be of prime
importance, since little is known about the bio-
chemical mechanisms responsible for the effects of
this group of compounds.
XO is a highly versatile enzyme, which is widely
distributed among species and within the various
tissues of mammals.10 XO exhibits a broad activity
toward reducing substrates. It can hydroxylate a
wide variety of purines (notably xanthine and
hypoxanthine), pteridines, related aromatic hetero-
cycles, and also a range of aliphatic and aromatic
aldehydes, taking these to the corresponding
carboxylic acids, with concomitant reduction of
molecular oxygen.11 – 13 In XO-catalysed reactions,
oxygen is reduced by one or two electrons giving rise
to superoxide radical (O2
·2) or hydrogen peroxide
(H2O2).
14,15 Consequently, xanthine oxidase is con-
sidered to be an important biological source of
reactive oxygen species (ROS), which induce
oxidative stress and are involved in many patho-
logical processes such as inflammation, atherosclero-
sis, cancer and aging.16 It has also been shown that
xanthine oxidase decomposes low molecular weight
S-nitrosothiols (e.g. S-nitrosoglutathione and S-
nitrosocysteine) by superoxide-dependent and
*Corresponding author. Address: ICETA/CEQUP, Toxicology Department, Faculty of Pharmacy, University of Porto—Rua Anibal
Cunha, 164, 4050-047 Porto, Portugal. Tel.: 351-22-2078922. Fax: 351-22-2003977. E-mail: egracas@ff.up.pt
-independent mechanisms, and, according to the
availability of oxygen in the system, secondarily
leads to peroxynitrite formation.17 This may alter the
transport and storage of nitric oxide (NO) by S-
nitrosothiols and the activity of proteins that are
regulated by S-nitrosylation. Thus, the superoxide
radical destroys the endothelium-derived vascular
relaxing factor (nitric oxide) causing vascular
constriction.18 It is of note that XO tissue levels are
increased after ischaemia reperfusion19 with serum
levels increased in hepatitis20 and brain tumours.21 It
is also known that an extensive metabolism of
xanthine by XO will increase body uric acid levels.
Due to the low solubility of uric acid, there is a
tendency for urate crystals to be deposited in the
urinary tract and in the synovial fluid of joints, a
process associated with painful inflammation, desig-
nated gout.22 Therefore, XO inhibitors are expected
to be therapeutically useful for the treatment of the
aforementioned pathological states.
The aim of this study was to evaluate the activity
profile of some synthetic 2-styrylchromone deriva-
tives as inhibitors of XO. Structure–activity relation-
ship data was obtained by comparing ten synthetic 2-
styrylchromones 1–3 (Figure 1) and a positive
control, allopurinol.
MATERIALS AND METHODS
Reagents
Xanthine and xanthine oxidase (XO) grade I from
buttermilk (EC 1.1.3.22), were purchased from Sigma.
The other chemicals were obtained from Merck. All
reagents were of analytical grade.
2-Styrylchromones 1 – 3 were obtained from
20-hydroxyacetophenones and cinnamic acid
derivatives.23 – 25
Xanthine Oxidase Activity
The effect of the tested compounds on XO activity
was evaluated by measuring the formation of uric
acid from xanthine in a double beam spectropho-
tometer (Shimadzu 2600), at room temperature. The
reaction mixtures in the sample wells consisted of
xanthine (400mL, 44mM final concentration), XO in
EDTA 0.1 mM (100mL, 0.29 U/ml final concen-
tration), and test compounds (100mL, in various
concentrations). The test compounds were dissolved
in DMSO. Xanthine was dissolved in NaOH 1mM,
and subsequently in phosphate buffer 50 mM with
EDTA 0.1 mM, pH 7.8. The absorbance was
measured at 295 nm for 2 min.
Additionally, this procedure was repeated for
some compounds with several concentrations of
xanthine (5.5, 11, 22, and 44mM), in order to evaluate
the type of inhibition using the Lineweaver–Burk
plot.
Statistical Analysis
Each separate experiment for XO inhibition was
conducted in duplicate, in a minimum of 5 assays per
tested compound. The results are expressed as
mean ^ SE: IC50 values were determined from plots
of concentration vs percentage inhibition curves.
RESULTS
All the tested 2-styrylchromone derivatives 1–3 were
found to be inhibitors of the XO-mediated oxidation
of xanthine to uric acid in a concentration-dependent
manner (Table I). IC50 values of the tested
compounds are also listed in Table I. Allopurinol, a
known xanthine oxidase inhibitor clinically used in
the treatment of gout,26 was also very effective in the
present assay, giving an IC50 of 5:43 ^ 0:80mM (Table
I). Four of the tested 2-styrylchromones were found
to be more potent than this drug and the rank order
of xanthine oxidase inhibition was 3c . 3b . 1d .
3a . allopurinol . 2c . 1c . 2b . 1b . 2a . 1a
(Table I).
Kinetic studies were performed in order to
determine the type of inhibition of these compounds.
Lineweaver–Burk plots (Figure 2) indicate that the
FIGURE 1 Structure of the tested 2-styrylchromones 1–3.
inhibition by the most potent compound 3c, as well
as two other representative compounds 1d and 2c,
was of a non-competitive inhibition type.
DISCUSSION
Although the chemical structure of 2-styryl-
chromones gives a good indication of its potential
as a XO inhibitor, to our knowledge the present study
clearly demonstrates this activity for the first time.
From the results obtained in the present study, some
considerations about the structure–activity relation-
ships can be made. The catechol group linked to the
styryl moiety of the molecule (compounds 3a–c)
strongly contributes to the inhibition of xanthine
oxidase. In fact, the absence of hydroxyl groups in
the aromatic ring linked to the styryl moiety
(compounds 1a–d), or the presence of only one p-
phenolic group (compounds 2a–c) substantially
decreased the inhibition. Interestingly, caffeic acid,
also a styryl bearing catechol compound, is a strong
inhibitor of XO, with an IC50 of around 20–70mM,
depending on the experimental conditions.27,28 The
a,b-unsaturated double bond plays a very important
role in the XO inhibition of caffeic acid.28 The low
IC50 found for 3c is probably the result of a
potentiation of effects by the catechol group linked
to the styryl moiety of the 5,7-dihydroxylated
benzopyrone.
The hydroxylation pattern in the benzopyrone
moiety was important for the potency of XO
inhibition. Indeed, the unsubstituted 2-styrylchro-
mone 1a was practically inactive. This finding is in
agreement with previous studies with flavones8 and
coumarins.7 The presence of hydroxyl groups at the
C-5 and C-7 positions of the benzopyrone lead to an
observed increase in activity, when compared with
the presence of only one substitution, which is also in
FIGURE 2 Lineweaver–Burk plots in the absence (control) and in
the presence of 2-styrylchromones 2c, 3c, and 1d with xanthine as
the substrate. V  DA=min; S  xanthine (mM).
TABLE I The inhibitory effects of 2-styrylchromones 1–3 and allopurinol on xanthine oxidase activity
Concentration (mM)/% inhibition ^ SE*
Compound 0.625 2.5 10 25 50 100 IC50 (mM)
1a 4.34 ^ 0.80 12.04 ^ 1.83 32.99 ^ 2.65 .100
1b 6.24 ^ 0.95 18.77 ^ 2.18 52.03 ^ 5.83 86.45 ^ 3.15 52.06 ^ 4.38
1c 15.93 ^ 0.58 35.48 ^ 1.58 61.17 ^ 1.01 81.56 ^ 1.48 16.96 ^ 0.85
1d 21.1 ^ 1.51 48.28 ^ 0.70 76.99 ^ 1.19 90.26 ^ 0.77 2.52 ^ 0.08
2a 13.6 ^ 1.14 25.51 ^ 1.72 37.44 ^ 1.51 62.37 ^ 2.53 77.35 ^ 3.38
2b 17.77 ^ 1.43 38.45 ^ 1.98 57.12 ^ 2.64 74.76 ^ 2.39 19.64 ^ 2.97
2c 25.2 ^ 1.63 52.79 ^ 1.84 71.51 ^ 1.8 81.87 ^ 1.42 9.46 ^ 1.08
3a 14.33 ^ 0.98 38.89 ^ 2.26 69.83 ^ 1.28 4.36 ^ 0.57
3b 26.42 ^ 1.11 54.32 ^ 1.68 81.74 ^ 1.22 2.03 ^ 0.19
3c 54.31 ^ 2.03 76.74 ^ 1.42 92.19 ^ 0.98 0.55 ^ 0.03
Allopurinol 31.41 ^ 2.32 64.73 ^ 1.18 85.06 ^ 0.61 92.87 ^ 0.45 5.43 ^ 0.80
* n  5:
agreement with the similar activity profile for
flavones.29 It was found that the 7-hydroxylated
derivatives were more potent than the respective
5-hydroxylated derivatives. Again, the importance of
the C-7 hydroxylation has also been observed for the
XO inhibitory activity of flavone derivatives8 and
coumarin derivatives.30 Some other interesting
structural features of flavones including the presence
of the double bond between C-2 and C-3 (essential
for planarity of the molecule) as well as the absence
of a hydroxyl at C-3 enhances XO inhibitory
activity.29 Furthermore, the presence of an additional
hydroxyl at C-6 has been shown to considerably
increase the activity of some flavones7 and decrease
it in others.29 Although such types of styrylchro-
mones have not been obtained to date, it seems to be
of interest to evaluate their activity further.
The mode of inhibition of the studied com-
pounds was of a mixed non-competitive inhibition
type. This means that the binding site of these
compounds to XO is not the molybdenum site but
more probably the iron–sulfur group of the
enzyme. However, this type of inhibition is not
the rule for benzopyrone-bearing compounds, as
can be inferred from the competitive or uncompe-
titive mode of inhibition reported for various
flavonoids,6,31 7-hydroxycoumarin and esculetin.30,32
In conclusion, various 2-styrylchromones
were found to be potent XO inhibitors and
should be further evaluated as potential agents
for the treatment of pathologies related with
its activity, e.g. gout, ischaemia/reperfusion
damage, hypertension, hepatitis and cancer.
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